Brief: Mesoblast Says FDA Grants Orphan Drug Designation For Revascor
15/02/2024 01:26
Feb 15 (Reuters) - Mesoblast Ltd MSB.AX :
* FDA GRANTS ORPHAN DRUG DESIGNATION FOR REVASCOR
Source text for Eikon: ID:nASX5L51Ry
Further company coverage: MSB.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mesoblast
See all newsBrief: Mesoblast William Burns To Retire From Board At 2026 AGM
Brief: Mesoblast Says Q1 Net Revenues Up 44%
Australia's Mesoblast hits one-month high on upbeat quarterly update
Australia's Mesoblast drops as Bell Potter cuts target price after key drug misses sales view
Brief: Mesoblast Says FDA Approves New Potency Assay For Commercial Ryoncil